et al. J Clin Endocrinol Metab 2016 [Epub ahead of print] The March edition of the JCEM included a series of four notable articles highlighting the presentation, diagnosis, management and epidemiology of hypoparathyroidism. Following the recently published European Society of Endocrinology clinical guidelines, these constitute the consensus guidelines from the first International Conference on the Management of Hypoparathyroidism.
The March edition of the JCEM included a series of four notable articles highlighting the presentation, diagnosis, management and epidemiology of hypoparathyroidism. Following the recently published European Society of Endocrinology clinical guidelines, these constitute the consensus guidelines from the first International Conference on the Management of Hypoparathyroidism.
Of the four articles, the Epidemiology and Diagnosis statement paper may be of particular interest to the clinical biochemistry laboratory and discusses the use of particular PTH assays. It advocates the use of second-and third-generation PTH assays (specific for the PTH carboxy-and amino-terminals, respectively) for the diagnosis of hypoparathyroidism. This point has, to my knowledge, not been mentioned in previous guidelines. Interestingly, this paper suggests that the third-generation assays, while theoretically better, have not proven superior in clinical practice. The paper mentions a recent report (J Bone Miner Res 2015; 30: 1803-1813) describing the influence of genetic mutations on the diagnostic performance of the secondand third-generation assays.
In summary, this series of papers addresses key aspects of diagnosis, evaluation and management of hypoparathyroidism. Non-alcoholic steatohepatitis (NASH) is the commonest cause of chronic liver disease globally and results in both liver-and cardiovascular-related morbidity and mortality. There are currently no drug therapies licensed for NASH. The long-acting glucagon-like peptide-1 (GLP-1) analogue, liraglutide, is licensed for the treatment of type 2 diabetes and is known to improve steatosis in mouse models and isolated human hepatocytes. Thus far, however, data on the effects of GLP-1 analogues in human liver have been limited to case reports and retrospective studies of liver enzymes in patients with type 2 diabetes. Yu et al. have performed a randomized, doubleblind, placebo-controlled trial of liraglutide in UK patients with histologically confirmed NASH. Fiftytwo patients received either 1.8 mg daily of liraglutide or placebo for 48 weeks. In summary, treatment with liraglutide led to a significant improvement in histological steatosis and hepatocyte ballooning, with reduced progression of fibrosis, compared with placebo.
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Given the well-established metabolic improvements seen with liraglutide treatment, these results are not a surprise but are important nevertheless as the first trial to report beneficial effects of GLP-1R agonism in NASH. 
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